The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014, as retained as part of the law of England and Wales. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Press release
2 March 2022
Cellular Goods PLC
('Cellular Goods' or 'the Company')
Exercise of Warrants
Cellular Goods (LSE: CBX), a UK-based wellness company that provides premium consumer products based on lab-made cannabinoids, announces that it has issued 2.5 million ordinary shares in the Company ("Ordinary Shares") to satisfy the exercise of warrants. The exercise price is 1p per Ordinary Share.
Application has been made to admit 2.5 million Ordinary Shares to trading on the London Stock Exchange, and admission is expected to be granted at 8am on 4 March 2022. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares.
Following admission, the total number of Ordinary Shares in issue will be 507,250,000 and the total number of voting rights will therefore be 507,250,000. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The Directors of the Company accept responsibility for this announcement.
For further information please contact:
| Cellular Goods | |
| Anna Chokina Chief Executive Neil Thapar Investor Relations | via Tancredi +44 207 887 7633
+44 787 645 5323 |
| Tennyson Securities | |
| Corporate Broker Peter Krens |
+44 207 186 9030 |
| Novum Securities | |
| Corporate Broker Colin Rowbury Jon Belliss |
+44 207 399 9427 |
| Tancredi Intelligent Communication | |
| Media Relations Helen Humphrey Gabriela Amaya Garcia Edward Daly Charlie Hobbs |
+44 744 922 6720 +44 791 503 5294 +44 786 143 0057 +44 789 755 7112
|
About Cellular Goods PLC:
Cellular Goods is a UK-based wellness company that provides premium products based on lab-made cannabinoids. It was established in August 2018 to develop efficacy-led and research-backed cannabinoid-powered wellness products. The initial focus is on three product verticals: Function Better, Feel Better and Look Better. These three verticals encompass Cellular Goods' premium CBG skincare and CBD ingestible and topical athletic recovery products, with the first products launched in December 2021 initially through the Company's website. The Company's shares are listed on the main market of the London Stock Exchange. www.cellular-goods.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
